UBS Group’s Tetraphase Pharmaceuticals TTPH Stock Holding History
Bought
Maintained
Sold
UBS Group's TTPH Position: Q3 2020 in Review
UBS Group sold out of Tetraphase Pharmaceuticals (TTPH) in Q3 2020, closing a stake of 2,925 shares — an estimated $7K sold.
UBS Group first reported a position in TTPH in Q3 2013 and held it in 26 quarters. The position peaked at $1.83M in Q2 2015. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- UBS Group reported no remaining Tetraphase Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
- UBS Group sold 2,925 Tetraphase Pharmaceuticals shares in Q3 2020, an estimated $7K.
- UBS Group first reported a position in Tetraphase Pharmaceuticals in Q3 2013 and held it in 26 quarters.
- UBS Group's Tetraphase Pharmaceuticals position peaked at $1.83M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals as of Q3 2020.
Based on UBS Group's 13F filing for Q3 2020, filed 12 Nov 2020.